

IN THE CLAIMS

The status of the claims is as follows:

Claims 1-17: (Canceled).

18. (New) An isolated peptide which comprises the amino acid sequence of the formula:

X-Y-Thr-Trp-Asn-Gln-Met-Asn-Leu (SEQ ID NO: 4)

wherein

X represents Ala, Abu, Arg, Lys, Orn, Cit, Leu, Phe or Asn,

Y represents Tyr or Met, and

the peptide induces cytotoxic T lymphocytes (CTLs).

19. (New) The peptide according to Claim 18, which comprises
Ser-Tyr-Thr-Trp-Asn-Gln-Met-Asn-Leu (SEQ ID NO: 5),
Ala- Tyr-Thr-Trp-Asn-Gln-Met-Asn-Leu (SEQ ID NO: 6),
Abu- Tyr-Thr-Trp-Asn-Gln-Met-Asn-Leu (SEQ ID NO: 7),
Arg- Tyr-Thr-Trp-Asn-Gln-Met-Asn-Leu (SEQ ID NO: 8),
Lys- Tyr-Thr-Trp-Asn-Gln-Met-Asn-Leu (SEQ ID NO: 9),
Orn- Tyr-Thr-Trp-Asn-Gln-Met-Asn-Leu (SEQ ID NO: 10),
Cit- Tyr-Thr-Trp-Asn-Gln-Met-Asn-Leu (SEQ ID NO: 11),
Leu- Tyr-Thr-Trp-Asn-Gln-Met-Asn-Leu (SEQ ID NO: 12),
Phe- Tyr-Thr-Trp-Asn-Gln-Met-Asn-Leu (SEQ ID NO: 13),
Asn- Tyr-Thr-Trp-Asn-Gln-Met-Asn-Leu (SEQ ID NO: 14), or
Ala- Met-Thr-Trp-Asn-Gln-Met-Asn-Leu (SEQ ID NO: 16).

20. (New) The peptide according to Claim 18, which consists of any one of the amino acid sequences selected from a group consisting of SEQ ID NOs: 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 16.

21. (New) A pharmaceutical composition for inducing CTLs, which comprises the peptide according to Claim 18 and a pharmaceutically acceptable carrier.

22. (New) A pharmaceutical composition for inducing CTLs, which comprises the peptide according to Claim 19 and a pharmaceutically acceptable carrier.

23. (New) A pharmaceutical composition for inducing CTLs, which comprises the peptide according to Claim 20 and a pharmaceutically acceptable carrier.

24. (New) A method of treating cancer, comprising administering an effective amount of the peptide of Claim 18 to a subject in need thereof.

25. (New) A method of treating cancer, comprising administering an effective amount of the peptide of Claim 19 to a subject in need thereof.

26. (New) A method of treating cancer, comprising administering an effective amount of the peptide of Claim 20 to a subject in need thereof.

27. (New) A method of inhibiting the development of cancer, comprising administering an effective amount of the peptide of Claim 18 to a subject in need thereof.

28. (New) A method of inhibiting the development of cancer, comprising administering an effective amount of the peptide of Claim 19 to a subject in need thereof.

29. (New) A method of inhibiting the development of cancer, comprising administering an effective amount of the peptide of Claim 20 to a subject in need thereof.